ClinicalTrials.gg
Not yet recruitingNCT07713199Updated Nov 6, 2026

Free Soft Tissue Grafts (FSTG) Using Autograft Palatal Donor Tissue vs. Xenograft Collagen Matrix (Zderm™)

An interventional study of Zderm in Gingival Recession Localized Moderate and Dental Implant, sponsored by The University of Texas Health Science Center at San Antonio. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by The University of Texas Health Science Center at San Antonio · Not applicable, Interventional, and Treatment

Updated Nov 6, 2026Start date movedTitle changedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 89 Years
Sex
All
01

Study summary

Participant in this study are asked to participate because they have teeth or dental implants that were identified as having very little gum tissue and would benefit from gum tissue graft surgery. This study has 2 groups that differ only in the material that will be used at the graft site:

  • Gum tissue taken from the patient's own palate (standard of care group)
  • Commercially available collagen matrix derived from porcine (pig) Achilles tendon (FDA-approved for the surgery done in this study).

Both materials have been in use in dental practices for many years, but no studies have directly compared the outcomes between palatal tissue and the porcine collagen matrix we will use in this study.

Participants will be randomized into one of the 2 groups using sealed envelopes (the process is like flipping a coin). All the study visits will take place during regular dental appointments that would be scheduled even if not participating in this research.

Read the detailed description

The investigators are examining the amount of gingiva gained when using 2 different types of donor tissue to do the graft surgery: either gum tissue from the patient's palate (standard of care) or commercially available tissue called a "collagen matrix" that comes from an animal source (the Achilles tendon of pigs). Palatal tissue has been used for over 70 years for this purpose, while animal sources have been used for about 15 years. So far, no studies have been done to see if there are any differences in the amount of new gum tissue we see when we use the palatal tissue approach versus the animal tissue approach. The purpose of this study is to compare the 2 approaches during a period of 6 months after graft surgery to determine if the change in gingiva is similar or different between the 2 approaches.

Teeth are surrounded by soft tissue called gingiva (gums). Sometimes, the amount of gingiva is very small, which can lead to problems such as receding gums, pain on toothbrushing/flossing, and an increased risk for gum diseases. In such instances, dentists commonly perform surgery procedures to increase the amount of gum tissue around teeth or dental implants. "Gum grafting" involves taking a small piece of tissue from one location (called the donor site and donor tissue) and transplanting it to the area where the amount of gingiva is inadequate (called the recipient site because this location will receive the donor tissue).

02

Conditions studied

  • Gingival Recession Localized Moderate
  • Dental Implant

Browse trials for

Keywords

  • Tissue graft surgery
  • Receding gums
  • Keratinized tissue
03

In context

Gingival Recession

426 studies on the registry are indexed under Gingival Recession; 106 are open to participants now.

This study's planned enrollment of 68 is above the median of 30 across 390 interventional studies indexed under Gingival Recession.

Browse Gingival Recession studies →

Lead sponsor

The University of Texas Health Science Center at San Antonio is the lead sponsor of 445 studies on the registry; 89 are open to participants now.

Of its 65 completed or terminated interventional studies of FDA-regulated products, 35 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient aged 18 to 89
  • One or more teeth/dental implants, excluding 3rd molars, that have been identified by dental faculty as requiring augmentation of KT
  • A FSTG is indicated and treatment planned to augment the KT. Coverage of exposed root surfaces is not indicated or intended. Patients needing root coverage surgical procedures re not eligible for enrollment (similar to our past studies, see references 11,12)
  • Female patients who have undergone a hysterectomy, tubal ligation, or menopause, and non-pregnant women of as eligible.
  • Patients who are nonsmokers or former smokers are eligible. Current smokers may also be included if they smoke \<10 cigarettes per day (less than or equal to 10 cigarettes per day).

Exclusion criteria

Exclusion Criteria:

  • Patients with a known allergy to collagen of animal origins.
  • Patients who will not cooperate with the follow-up schedule.
  • Patients will not be entered who are mentally incompetent, prisoners, or pregnant.
  • Patients who require soft tissue grafting specifically to treat exposed root coverage (gingival recession)
  • Pregnant women or women intending to become pregnant during the study period (as confirmed verbally; an over-the-counter pregnancy test will be provided if pregnancy status is unknown or suspected).
  • Patients who become pregnant during the study will be withdrawn and standard care will be delivered.
  • Patients with active or systemic infections other than periodontitis; a disease entity, condition or therapeutic regimen which decreases probability of soft tissue healing, e.g., poorly controlled diabetes, diseases, long-term therapy.
  • Smokers who smoke >10 cigarettes per day (more than 10 cigarettes per day)
  • People who live more than 50 miles from the UTSA School of Dentistry are not eligible.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Active comparator
    Test Group Porcine Collagen Matrix

    The recipient site to which the Zderm™ material will be placed will be prepared with a standard of care split thickness tissue flap at the site which needs augmentation of the KT.

    Device: Zderm

  • No intervention
    Control Group - Palatal Graft

    The recipient site to which the palatal autogenous donor tissue will be placed will be prepared with a standard of care split thickness tissue flap at the site which needs augmentation of the KT. The harvested tissue will be trimmed to the required size and shape with surgical scissors as indicated by the number of tooth/implant sites to be augmented

Interventions

  • DeviceZderm

    The material used at the graft recipient site is xenograft collagen soft tissue matrix derived from porcine Achilles tendon (ZdermTM)

06

What researchers measure

Primary outcomes

  1. Change in width of Keratinized Tissue

    The change in vertical distance from the gingival margin to the keratinized base of the grafted site measured on digital scans, and from the fixed reference point on the customized measurement stent to the keratinized base of the grafted site measured intra-orally.

    Time frame: Baseline to 6 months

Secondary outcomes

  1. Graft dimension width change

    Dimensional change ("shrinkage") of the grafted area during healing will be assessed by measuring graft width (vertical dimension)

    Time frame: Baseline to 6 months

  2. Graft Length Change

    Dimensional change ("shrinkage") of the grafted area during healing will be assessed by measuring graft length (horizontal dimension).

    Time frame: Baseline to 6 months

  3. Dimensional area change

    Dimensional change of the grafted area during healing will be assessed by endpoints of graft width (vertical dimension), graft length (horizontal dimension) to measure graft area.

    Time frame: Baseline to 6 months

  4. Length of surgery in minutes

    The length of surgery in minutes will be assessed by use of a standard timer. The timer will start when the first incision is made. The timer will stop 3 minutes after the final suture is placed and pressure has been applied at the recipient surgery site.

    Time frame: Time to complete surgery (approximately 2-3 hours)

  5. Numerical rating score for color match

    A 21-point numerical rating scale (NRS-21) with which patients and clinicians can assess color match of the grafted area to the surrounding soft tissue. The NRS-21 scale allows scores ranging from 0 (worst color match) to 10 (best color match) in increments of 0.5.

    Time frame: One month to 6 months

  6. San Antonio Texture index (SaTi)

    A 4-point texture index score for clinicians to assess the tissue texture match of the grafted area to the surrounding soft tissue. The SATi is a four-point rating scale as follows: 1. Major variation in texture compared to adjacent gingiva 2. Moderate variation in texture compared to adjacent gingiva 3. Minor variation in texture compared to adjacent gingiva 4. Identical to adjacent gingiva= a bettter outcome

    Time frame: One month to six months

  7. Pain Score on Numeric Rating Scale (NRS)

    Pain associated with the surgery will be assessed by patients using NRS-21 that ranges from 0 to 10 in 0.5 increments, with 0 indicating no pain and 10 indicating intolerable pain. Patients will record NRS-21 scores on paper forms

    Time frame: 24 to 168 hours after surgery

  8. Analgesic consumption

    Participants will count and document number of analgesics (ibuprofen and acetaminophen) taken after surgery

    Time frame: 24 to 168 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — There is a plan to make Individual Participant Data available once it has been de-identified. Data will be shared as summary results on ClinicalTrials.gov and after publication in a peer review journal.

Supporting information: Study protocol, Statistical analysis plan

Time frame: After study end and data analysis is complete.

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Start date
Sep 15, 2026→Nov 30, 2026
Nov 6, 2026
Title
Free Soft Tissue Grafts (FSTG) Using Autograft Palatal Donor Tissue vs. Xenograft Collagen Matrix (Zderm™)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Start date Sep 15, 2026→Nov 30, 2026
    Title Free Soft Tissue Grafts (FSTG) Using Autograft Palatal Donor Tissue vs. Xenograft Collagen Matrix (Zderm™)
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07713199
Responsible party
Sponsor
First posted
Jul 20, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Oct 31, 2028 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Brian L Mealey, DDS, MS
Contact
mealey@uthscsa.edu
210-567-3589
Angela Palaiologou-Gallis, DDS
Contact
palaiologouA@uthscsa.edu
210-567-3567
Brian L Mealey, DDS, MS
principal investigator · The University of Texas Health Science Center at San Antonio

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion